Octaplex (Human Coagulation Factor Ix, Protein C, Human Coagulation Factor Vii, Protein S, Human Coagulation F)

Octaplex is a plasma‑derived coagulation concentrate that acts on the intrinsic pathway of the clotting cascade.

• Hemophilia B: Provides functional Factor IX to control and prevent bleeding episodes.
• Acquired Factor IX deficiency: Restores clotting ability in patients with deficiency due to liver disease or vitamin K antagonist therapy.
• Peri‑operative management: Supplies necessary clotting activity for patients undergoing surgery who have low Factor IX levels.
• Congenital Factor IX deficiency (rare): Supports hemostasis in genetically deficient individuals.
• Trauma‑induced bleeding: Helps achieve hemostasis when severe bleeding is associated with low Factor IX activity.

• Octaplex supplies exogenous human Factor IX, a vitamin K‑dependent serine protease that participates in the intrinsic coagulation cascade. After intravenous infusion, the protein binds to activated Factor X on phospholipid surfaces, accelerating the conversion of prothrombin to thrombin, which then generates fibrin strands to form a stable clot and stop bleeding.

Octaplex may cause adverse reactions ranging from mild to severe.

Common Side Effects

• Injection site erythema: Redness and mild discomfort at the infusion site.
• Headache: Transient mild headache reported after infusion.
• Nausea: Occasional mild nausea during or after administration.
• Fever: Low‑grade temperature elevation within 24 hours post‑infusion.
• Mild arthralgia: Joint discomfort without swelling.

Serious or Rare Side Effects

• Anaphylaxis: Acute, potentially life‑threatening allergic reaction requiring immediate medical intervention.
• Thromboembolic events: Formation of clots in veins or arteries, especially with high plasma concentrations.
• Hemolytic transfusion reaction: Immune‑mediated destruction of red blood cells.
• Viral transmission risk: Potential for transmission of blood‑borne pathogens despite viral inactivation steps.
• Severe hypotension: Sudden drop in blood pressure during infusion.
• Disseminated intravascular coagulation: Widespread activation of clotting leading to bleeding and organ dysfunction.

Octaplex should be used with careful clinical monitoring and adherence to handling guidelines.

• Allergy assessment: Verify no known hypersensitivity to human plasma proteins before administration.
• Thrombotic risk: Evaluate patient history for thrombosis before high‑dose or repeated infusions.
• Hepatic impairment: Adjust monitoring in patients with liver disease affecting clotting factor synthesis.
• Concomitant anticoagulants: Use caution when patients are receiving warfarin or other anticoagulants.
• Pediatric use: Dose and monitoring requirements differ; follow specialist guidance.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplex can interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid)

• Direct oral anticoagulants (DOACs): May counteract the pro‑coagulant effect of Factor IX replacement.
• High‑dose aspirin or NSAIDs: Increase bleeding risk when combined with Factor IX deficiency.

Moderate Interactions (Monitor Closely)

• Warfarin: Requires careful INR monitoring as Factor IX may alter anticoagulant effect.
• Immunosuppressive biologics: May modify immune response to plasma‑derived proteins.
• Vaccines: Observe for enhanced local reactions when administered near infusion time.
• Antibiotics (e.g., vancomycin): Potential for additive infusion‑related reactions.
• Other plasma‑derived concentrates: Cumulative clotting factor load may raise thrombotic risk.